Updating the probability of study success for combination therapies using related combination study data

被引:1
|
作者
Graham, Emily [1 ,5 ]
Harbron, Chris [2 ]
Jaki, Thomas [3 ,4 ]
机构
[1] Univ Lancaster, STOR i Ctr Doctoral Training, Lancaster, England
[2] Roche Pharmaceut, Welwyn Garden City, England
[3] Univ Regensburg, Regensburg, Germany
[4] Univ Cambridge, MRC Biostat Unit, Cambridge, England
[5] Univ Lancaster, STOR i Ctr Doctoral Training, Lancaster LA1 4YF, England
基金
英国医学研究理事会; 英国工程与自然科学研究理事会;
关键词
Combination therapies; clinical trials; probability of success; Bayesian; assurance; CLINICAL-TRIALS; PHASE-II; TRASTUZUMAB; PERTUZUMAB; DOCETAXEL; POWER; END;
D O I
10.1177/09622802231151218
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Combination therapies are becoming increasingly used in a range of therapeutic areas such as oncology and infectious diseases, providing potential benefits such as minimising drug resistance and toxicity. Sets of combination studies may be related, for example, if they have at least one treatment in common and are used in the same indication. In this setting, value can be gained by sharing information between related combination studies. We present a framework that allows the study success probabilities of a set of related combination therapies to be updated based on the outcome of a single combination study. This allows us to incorporate both direct and indirect data on a combination therapy in the decision-making process for future studies. We also provide a robustification that accounts for the fact that the prior assumptions on the correlation structure of the set of combination therapies may be incorrect. We show how this framework can be used in practice and highlight the use of the study success probabilities in the planning of clinical studies.
引用
收藏
页码:712 / 731
页数:20
相关论文
共 50 条
  • [31] Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors
    Jones, Suzanne F.
    Infante, Jeffrey R.
    Spigel, David R.
    Peacock, Nancy W.
    Thompson, Dana S.
    Greco, F. Anthony
    McCulloch, William
    Burris, Howard A., III
    CANCER INVESTIGATION, 2012, 30 (06) : 481 - 486
  • [32] Glaucoma Research on Adeherence to Fixed Combination Eye drops in Japan (GRACE study) : A First Report
    Tsumura, Toyoaki
    Suzuki, Yasuyuki
    Kashiwagi, Kenji
    Yoshikawa, Keiji
    Suzumura, Hirotaka
    Maeda, Toshine
    Takeda, Ryuji
    Saito, Hitomi
    Araie, Makoto
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [33] Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
    Bhatnagar, Bhavana
    Zhao, Qiuhong
    Mims, Alice S.
    Vasu, Sumithira
    Behbehani, Gregory K.
    Larkin, Karilyn
    Blachly, James S.
    Blum, William
    Klisovic, Rebecca B.
    Ruppert, Amy S.
    Orwick, Shelley
    Oakes, Christopher
    Ranganathan, Parvathi
    Byrd, John C.
    Walker, Alison R.
    Garzon, Ramiro
    LEUKEMIA & LYMPHOMA, 2020, 61 (02) : 387 - 396
  • [34] Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study
    N. Xenidis
    L. Chelis
    K. Amarantidis
    E. Chamalidou
    P. Dimopoulos
    N. Courcoutsakis
    A. Tentes
    A. Chiotis
    P. Prassopoulos
    S. Kakolyris
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 477 - 484
  • [35] Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
    Okusaka, T.
    Nakachi, K.
    Fukutomi, A.
    Mizuno, N.
    Ohkawa, S.
    Funakoshi, A.
    Nagino, M.
    Kondo, S.
    Nagaoka, S.
    Funai, J.
    Koshiji, M.
    Nambu, Y.
    Furuse, J.
    Miyazaki, M.
    Nimura, Y.
    BRITISH JOURNAL OF CANCER, 2010, 103 (04) : 469 - 474
  • [36] Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
    Michaelson, M. D.
    Zhu, A. X.
    Ryan, D. P.
    McDermott, D. F.
    Shapiro, G. I.
    Tye, L.
    Chen, I.
    Stephenson, P.
    Patyna, S.
    Ruiz-Garcia, A.
    Schwarzberg, A. B.
    BRITISH JOURNAL OF CANCER, 2013, 108 (07) : 1393 - 1401
  • [37] A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
    Xu, Dongdong
    Wu, Jiang
    Yu, Jing
    Yang, Yuqing
    Wen, Xinxin
    Yang, Jixin
    Wei, Hongliang
    Xu, Xiaolong
    Li, Yike
    Yang, Liu
    Wang, Lei
    Wang, Yijia
    Ma, Wen
    Li, Nanlin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [38] A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
    Janni, Wolfgang
    Sarosiek, Tomasz
    Karaszewska, Boguslawa
    Pikiel, Joanna
    Staroslawska, Elzbieta
    Potemski, Piotr
    Salat, Christoph
    Brain, Etienne
    Caglevic, Christian
    Briggs, Kathryn
    DeSilvio, Michelle
    Marini, Luca
    Papadimitriou, Christos
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (03) : 493 - 505
  • [39] Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study
    You, Shuhui
    Sang, Die
    Xu, Fei
    Luo, Ting
    Yuan, Peng
    Xie, Yizhao
    Wang, Biyun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [40] Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study
    Xenidis, N.
    Chelis, L.
    Amarantidis, K.
    Chamalidou, E.
    Dimopoulos, P.
    Courcoutsakis, N.
    Tentes, A.
    Chiotis, A.
    Prassopoulos, P.
    Kakolyris, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 477 - 484